Leave Your Message

Lacticaseibacillus paracasei G15 Pet Probiotics Powder - China Suppliers & Factory - CCTCC M 20232497

Deposite: CCTCC M 2020833

Shelf life: 24 months

Storage conditions: Stored at -18℃or lower

Health Benefits

Discover the high-quality CCTCC M 20232497 product, expertly crafted to meet your needs. Our China-based factory is dedicated to producing top-notch products, ensuring that we are among the leading suppliers in the industry. With a focus on quality and customer satisfaction, our CCTCC M 20232497 product stands out in the market, catering to a diverse range of applications. Trust our experienced suppliers to deliver exceptional value and performance from our trusted China factory.

    Detailed Information
    Customization Products customized are acceptable.
    Potency Options 10B CFU/g, 50B CFU/g, 100B CFU/g, 200B CFU/g, 300B CFU/g, 400B CFU/g, 500B CFU/g
    Shelf Life 24 months
    Storage Conditions Stored at -18℃ or below
    Applications
    Lacticaseibacillus Paracasei G15 Postbiotics Powder (5)3ar
    Dairy
    Lacticaseibacillus Paracasei G15 Postbiotics Powder (4)oxf
    Food
    Fermented Beveragesmmc
    Fermented Beverages
    Pharmaceuticals1am
    Pharmaceuticals
    Biotechnologyksp
    Biotechnology
    Feed AdditivePetdt0
    Feed Additive/Pet
    Literature
    • 1. Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota.
    • 2. Targeting gut microbiota Lactobacillus alleviated type 2 diabetes via inhibiting LPS secretion and activating GPR43 pathway.
    Academic Research
    "Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota" — This research paper examines the antidiabetic effects and possible mechanisms of two Lactobacillus strains (G15 and Q14) on high-fat diet and streptozotocin-induced type 2 diabetes (T2D) in rats.
    Background
    • The prevalence of type 2 diabetes (T2D) is increasing and the search for new therapeutic approaches is crucial.
    • Gut flora plays an important role in the pathogenesis of T2D, influencing disease progression by regulating energy metabolism, insulin resistance, and inflammation, among other pathways.
    • Probiotics, especially lactobacilli, have been shown to have beneficial effects on diabetes-related parameters, but their mechanism of action is unclear.
    • The aim of this study was to evaluate the effects of two lactic acid bacteria (G15 and Q14) isolated from traditional Chinese fermented dairy products on T2D and their mechanisms.
    Research Methods
    • The researchers used a high-fat diet and a streptozotocin-induced T2D rat model.
    • The experiment was divided into 7 groups: normal control, diabetic control, metformin-treated, G15-treated, G15+metformin-treated, Q14-treated and Q14+metformin-treated.
    • Researchers assessed the effects of probiotics on blood glucose tolerance, gut flora, gut permeability, inflammation and islet damage.
    Study Results
    • G15 and Q14 significantly improved blood glucose tolerance and lowered glycated haemoglobin (HbA1c) levels in T2D rats, suggesting their antidiabetic effects.
    • Probiotic treatment reduced intestinal permeability and improved epithelial barrier function by modulating intestinal flora, thereby reducing circulating LPS and inflammatory cytokines (e.g., IL-1β and IL-8), and ultimately attenuating inflammatory state and pancreatic islet β-cell dysfunction.
    • Combination treatment of Q14 with metformin reversed thymic atrophy, while both G15 and Q14 reduced circulating levels of IL-6, suggesting the immunomodulatory potential of these strains.
    Conclusions
    • G15 and Q14 have antidiabetic effects in T2D rats through the regulation of gut flora, intestinal permeability and inflammation pathways.
    • These results provide new ideas for the biotherapeutic application of traditional fermented foods and their functional components in the treatment of diabetes.
    Significance of the study
    • This study reveals the link between intestinal flora and T2D, and provides a theoretical basis for the development of novel diabetes treatments.
    • Probiotics, as functional components of traditional fermented foods, have potential applications in the treatment of diabetes.
    Future Research Directions
    • Further investigate the interaction mechanism between intestinal flora and epithelial barrier.
    • Explore in depth the effects of probiotics on the composition and function of intestinal flora.
    • Conduct longer experiments to assess the long-term effects of probiotics on immune-related parameters.
    Frequently Asked Questions
    What potencies are available for Lacticaseibacillus Paracasei G15?
    We offer a wide range of standard potencies: 10B CFU/g, 50B CFU/g, 100B CFU/g, 200B CFU/g, 300B CFU/g, 400B CFU/g, and 500B CFU/g. Customized specifications can also be accommodated upon request.
    How should Lacticaseibacillus Paracasei G15 be stored?
    To maintain optimal stability and potency, the product should be stored in frozen conditions at -18℃ or below. Under these conditions, it has a shelf life of 24 months.
    What are the key applications of this postbiotics powder?
    Lacticaseibacillus Paracasei G15 Postbiotics Powder is highly versatile and suitable for use in Dairy products, general Food, Fermented Beverages, Pharmaceuticals, Biotechnology formulations, and Feed Additives/Pet food.
    What does academic research suggest about its antidiabetic effects?
    Studies show that G15 significantly improves glucose tolerance, reduces intestinal permeability, regulates gut microbiota, and lowers circulating inflammatory markers (like IL-1β, IL-8, and IL-6), helping alleviate type 2 diabetic symptoms in experimental models.
    Can I order customized formulations of this probiotic strain?
    Yes, customized product configurations are fully acceptable. We can tailor the specifications to meet your unique application requirements.

    Leave Your Message